Cargando…

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial

BACKGROUND: Lower body mass index (BMI) and weight loss have been associated with worse outcomes in some studies in patients with pulmonary fibrosis. We analyzed outcomes in subgroups by BMI at baseline and associations between weight change and outcomes in subjects with progressive pulmonary fibros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreuter, Michael, Bendstrup, Elisabeth, Jouneau, Stéphane, Maher, Toby M., Inoue, Yoshikazu, Miede, Corinna, Lievens, Dirk, Crestani, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999543/ https://www.ncbi.nlm.nih.gov/pubmed/36894966 http://dx.doi.org/10.1186/s12931-023-02371-z

Ejemplares similares

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
por: Jouneau, Stéphane, et al.
Publicado: (2020)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
por: Cottin, Vincent, et al.
Publicado: (2022)

Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
por: Matteson, Eric L., et al.
Publicado: (2023)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
por: Shumar, John N., et al.
Publicado: (2021)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
por: Kolb, Martin, et al.
Publicado: (2023)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2020)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework
por: Langford, Bryony, et al.
Publicado: (2021)

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
por: Maher, Toby M., et al.
Publicado: (2017)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON
por: Song, Jin Woo, et al.
Publicado: (2019)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality
por: Hyldgaard, Charlotte, et al.
Publicado: (2020)

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?
por: Kreuter, Michael, et al.
Publicado: (2022)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Eosinophil alveolitis in two patients with idiopathic pulmonary fibrosis
por: Brix, Ninna, et al.
Publicado: (2016)

Weight Loss and Hypertension in Obese Subjects
por: Fantin, Francesco, et al.
Publicado: (2019)

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
por: Noth, Imre, et al.
Publicado: (2021)

Clusters of comorbidities in fibrotic hypersensitivity pneumonitis
por: Prior, Thomas Skovhus, et al.
Publicado: (2022)

Economic consequences of idiopathic pulmonary fibrosis in Denmark
por: Hilberg, Ole, et al.
Publicado: (2018)

Towards a global initiative for fibrosis treatment (GIFT)
por: Molina-Molina, Maria, et al.
Publicado: (2017)

Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
por: Kreuter, Michael, et al.
Publicado: (2022)

Familial pulmonary fibrosis: a world without frontiers
por: Borie, Raphael, et al.
Publicado: (2019)

PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis
por: Kronborg-White, Sissel, et al.
Publicado: (2021)

Sustained self-regulation of energy intake. Loss of weight in overweight subjects. Maintenance of weight in normal-weight subjects
por: Ciampolini, Mario, et al.
Publicado: (2010)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
por: Salih, Goran Nadir, et al.
Publicado: (2016)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Risk factors for diagnostic delay in idiopathic pulmonary fibrosis
por: Hoyer, Nils, et al.
Publicado: (2019)

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2022)

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

HLA-G Is Widely Expressed by Mast Cells in Regions of Organ Fibrosis in the Liver, Lung and Kidney
por: Mouchet, Nicolas, et al.
Publicado: (2021)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lkg3ns6b9lib4sorrpis9ecvcf